Kinase Inhibitor Compound Profiling Service (KICP)

Specificity of lead compounds and mechanisms of actions uncovered

PRESS RELEASE - 2008 NOVEMBER 1

FOR IMMEDIATE RELEASE NOVEMBER 1, 2008

VANCOUVER, British Columbia – Kinexus Bioinformatics Corporation announced today that it has added a Kinase Inhibitor Compound Profiling Service (KICP) to its service portfolio. This new service is designed to assist researchers in ascertaining the specificity of lead compounds and their mechanisms of action for the selection of better drug candidates for clinical testing. Kinexus currently has over 200 human protein kinases available for screening with our KICP Service with plans to eventually increase that number to cover all 516 protein kinases.

The KICP Service provides a wide range of options to clients. Individual compounds may be profiled against a panel of protein kinase targets to establish the specificity of the compound. Alternatively, a panel of compounds may be tested against a single kinase target to identify a lead compound with the highest potency. Compounds may be tested either using a single dose or at multiple concentrations in order to allow in-depth IC determinations. In addition, the protein kinase assays can be performed under varying ATP concentrations to evaluate competition with respect to ATP. Compounds can be supplied by the client as DMSO stocks of known concentration, as solid material in vials, or in 96-well plates. Turnaround with our KICP Service is within two weeks of receipt of compounds for testing.

With more than 500,000 phosphorylation sites in the proteome targeted by kinases, it is critical to establish the specificity of any kinase drug candidate for clinical studies. The more specific the kinase inhibitors, the lower the chances of off targets that could compromise on the utility of the drug from toxicity and other undesired side-effects. This service relies on the use of gamma phosphate-radiolabeled ATP to phosphorylate peptide and recombinants protein substrates with purified and active preparations of human protein kinases. Kinexus performs the KICP Service under strict confidentiality, and all materials, information and results are used as directed by the client.

To learn more about the new Kinase Inhibitor Profiling Service or any of the other proteomics services available, please visit www.kinexus.ca. Kinexus Bioinformatics Corporation is a private, biotechnology company engaged in the research and development of innovative methods to understand the relationships of signaling proteins in cellular communication networks. The application of this knowledge positions Kinexus and its clients in drug development, rational drug design, disease diagnosis and personalized therapies to improve human health.

For further information, please contact Kinexus Bioinformatics Corporation toll free at 1-866-KINEXUS or visit our website at www.kinexus.ca